Cancer immunotherapy has witnessed a new renaissance with the advent of immune checkpoint inhibitors, which reactivate T cells and foster endogenous anti-tumor responses. The excellent results of immunotherapy in the field of melanoma, renal cancer, lung cancer, and other cancer types that have traditionally been known to be immunogenic, rekindled the interest of the oncology community in extending the benefits to all cancers including breast cancer (BC). In this review, we highlight the current state of using T cells as both markers for clinical practice and therapeutic options for BC.

中文翻译：

---

基于 T 细胞的乳腺癌免疫治疗

随着免疫检查点抑制剂的出现，癌症免疫疗法见证了新的复兴，它可以重新激活 T 细胞并促进内源性抗肿瘤反应。免疫疗法在黑色素瘤、肾癌、肺癌和其他传统上被认为具有免疫原性的癌症类型领域取得了卓越的成果，重新点燃了肿瘤学界将益处扩展到包括乳腺癌 (BC) 在内的所有癌症的兴趣. 在这篇综述中，我们强调了使用 T 细胞作为 BC 临床实践和治疗选择的标志物的现状。